NIKKEI 225
29,683.09 +84.43 (+0.29%) HANG SENG
25,319.72 -330.36 (-1.29%) GOLD FUTURES
1,861.20 -0.20 (-0.01%) DOW
35,870.95 -60.10 (-0.17%) BTC-GBP
43,072.73 -545.01 (-1.25%) CMC Crypto 200
1,402.14 -65.80 (-4.48%)
AB Science S.A. (ABSCF)
| Previous close | 14.32 |
| Open | 14.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 14.00 - 14.00 |
| 52-week range | 8.65 - 26.70 |
| Volume | |
| Avg. volume | 136 |
| Market cap | 580.327M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.54 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus
PRESS RELEASE AB SCIENCE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 TRIAL OF MASITINIB’S ANTIVIRAL ACTIVITY AGAINST THE SARS-CoV-2 (COVID-19) VIRUS Paris, 29 November, 2021, 8.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19. The study plans to enroll 78 patients, either non-hospitalized patients with mild disease
- Globe Newswire
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW GENERATION SYNTHETIC MICROTUBULE DESTABILIZER WITH THE ABILITY TO OVERCOME MULTIDRUG RESISTANCE AND HAS BROAD APPLICABILITY AS A POTENT ANTICANCER DRUG Paris, November 22, 2021, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that its Phase I/II study (AB18001) evaluating AB8939 in pati
- Globe Newswire
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO RESUME PATIENT ENROLMENT IN THE PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) STUDY AB19001 HAS NOW BEEN AUTHORIZED IN 15 COUNTRIES IN EUROPE, USA, AND OTHER REGIONS AND IS ACTIVELY ENROLLING PATIENTS Paris, 18 November 2021, 8.30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has received authorization from the United States Food and Drug Administration (FDA
